Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford is teaming up with four Berlin institutions, the Freie Universität Berlin, Humboldt-Universität zu Berlin, Technische Universität Berlin, the Charité – Universitätsmedizin Berlin, creating a new partnership which will open up exciting new initiatives across all academic disciplines.

Image courtesy of Shutterstock

The five universities will build on their strong existing research links and also create an environment for forging new projects in medicine, the sciences, humanities and social sciences. The agreement takes longstanding research relationships to a unique institutional level, marking the first common agreement of all four Berlin institutions with an international partner.

Under the new partnership, Oxford academics and researchers will have a platform to spend time in Berlin, collaborating with colleagues in the Charité teaching hospital, and the three Berlin universities, as well as the many other research institutes within the Berlin-Brandenburg region. At the same time, there will be support for academics, researchers and students from Berlin to spend time in Oxford’s departments and colleges.

Read more (University of Oxford website)

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).